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ABSTRACT
The Wilms’ tumor gene WT1 is a reliable marker for minimal residual disease assessment in acute leukemia patients. The study was
designed to demonstrate the potential use of WT1 to establish quality of remission in acute leukemia patients for early identification of
patients at high risk of relapse. A prospective study based on a quantitative Real–Time PCR (TaqMan) assay in 562 peripheral blood
samples collected from 82 acute leukemia patients at diagnosis and during follow-up was established. The evaluation of WT1 in periph-
eral blood samples after induction chemotherapy can distinguish the continuous complete remission patients from those who obtain
only an “apparent” complete remission and who could relapse within a few months. WT1 helps identify patients at high risk of relapse
soon after induction chemotherapy allowing post-induction therapy in high risk patients to be intensified.
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Introduction
Evaluation of minimal residual disease (MRD) in acute
myeloid leukemia (AML) after initial chemotherapy is impor-
tant to predict prognosis and may improve selection of the type
and intensity of post-remission treatment.1 The mainstays of
MRD studies in this setting include molecular tests, such as RT-
PCR amplification of chromosome translocations2,3 and multi-
dimensional flow cytometry detection of aberrant pheno-
types.4-6 The major obstacle in MRD detection by RT-PCR or
quantitative PCR (RQ-PCR) is represented by the limited per-
centage of AML patients presenting with detectable genetic
aberrations.7 This prompted several investigators to validate
the use of alternative markers for MRD detection suitable in
the vast majority of AML patients, and in particular to test WT1
expression as a universal marker of leukemic cells.8-12 The
Wilms’s tumor gene (WT1) codes for a transcription factor that
has been shown to be highly expressed in several hematopoi-
etic tumors including AML.8-12 Given the existence of back-
ground levels determined by WT1 expression in normal bone
marrow, studies using qualitative RT-PCR have provided con-
flicting results on the clinical value of this marker,13,14 whereas
most recent investigations by quantitative real-time RT-PCR
(RQ-PCR) clearly distinguished WT1 transcript amounts related
to AML cells, normal hemopoietic cells and post-chemothera-
py regenerating normal bone marrow cells.15,16 Therefore, longi-
tudinal RQ-PCR analysis of WT1 transcript amount may prove
clinically relevant for AML monitoring. Furthermore, since
WT1 expression in normal peripheral blood (PB) is about 1 log
lower than in normal BM with the majority of normal PB sam-
ples scoring negative, we hypothesized that sequential RQ-
PCR study of WT1 expression in PB might further improve the
sensitivity of MRD evaluation in AML and might also favor com-
pliance and sample availability. Finally, one of the main goals of
MRD assessment is represented by the possibility of identifying,
as soon as possible after induction chemotherapy the subset of
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patients who, although in CR, present a high risk of
relapse. This means these patients can be treated with
intensified chemotherapy protocols. To this purpose, in the
present study, we analyzed WT1 expression levels at diag-
nosis and during follow-up in 82 AML patients treated with
standard chemotherapy protocols. Our data indicate that
this approach provides important prognostic information in
AML by identifying patients at higher risk of relapse early
after induction chemotherapy.
Design and Methods
After obtaining informed consent, 562 peripheral blood
(PB) samples were collected from 82 AML patients. PB
sampling was performed at diagnosis, after each cycle of
chemotherapy and at sequential time intervals during fol-
low-up and at relapse. All cases were classified according
to FAB criteria, characterized at the cytogenetic level, and
screened by RT-PCR for the presence of the most frequent
fusion transcripts as previously described.17 The main clin-
ical and biological characteristics of the cohort of analyzed
patients are reported in Table1 (Online Appendix 1). Patients
under 60 years of age were treated following standard pro-
tocols established by the GIMEMA Cooperative Group.
(treatment details in Online Appendix 2)  After each cycle of
chemotherapy, a BM aspirate and biopsy were performed
in order to assess the response to therapy. Complete remis-
sion was defined according to standard criteria.18 PB sam-
ples were collected at diagnosis, after induction and consol-
idation chemotherapy. PB samples were collected 1-5 days
after the achievement of a neutrophil count 0.5×109/L. A
mean of 6.8 samples per patient were available for RQ-
PCR analysis (range 3-16). The median follow-up was 17
months (mean 20.7, range 5-66). Finally, as previously
described,10 70 PB samples and 22 BM samples from
healthy volunteers were used as control in order to define
the normal range of WT1 expression in healthy subjects. 
Cytogenetic and molecular analysis  
Cytogenetic and molecular analysis was performed in
all patients included in the study following standard
procedures.17,3 WT1 RQ-PCR reactions and fluorescence
values were measured as previously described.10,19
Results
As previously reported in other papers10,11 BM and PB
samples obtained from healthy volunteers express very
low levels of WT1. In our study, the majority of normal
PB are negative for WT1 expression and the mean value
in positive samples is 4±3 WT1 copies/104 ABL copies
(median 0, range 0-20). BM samples of normal donors
express a mean value of WT1 copies of 32±19 (median
28, range 0-90). A median value of 3,725 WT1 copies/104
ABL copies (mean value 7,222±12,496, range 68-95,549)
was detected in the 82 PB samples collected at diagnosis
and evaluated in the present study, and a median value of
30,212 (mean 57,830±22,980, range 416-122,714) in BM
samples. Seventy-one out of 82 patients achieved com-
plete remission (CR) and 11 patients were resistant to
induction chemotherapy. Twenty-seven out of 71
patients attaining CR after chemotherapy persisted in
remission with a median of 28 months of follow-up
(mean 30.3 months, range 12-60)(Figure 1) and 44
relapsed after a median of ten months (range 5-66) during
the follow-up period. (Figures 2 and 3). No significant dif-
ferences were observed in WT1 transcript amount at
diagnosis between the patients who persisted in CR and
those who relapsed, either in PB (p=0.13) or in BM
(p=0.27). No difference in the WT1 amount at diagnosis
was detected in patients resistant to chemotherapy when
compared with responders (p=0.05). Regression analysis
demonstrates the absence of correlation between WT1
expression and WBC count at diagnosis (r=0.0008).
There was no significant difference in WT1 transcript
within the FAB and cytogenetic risk subgroups and in
patients carrying ITD or point mutation of FLT3 when
compared with the wild type FLT3 group (p=0.29). WT1
quantitative assessment was performed in PB samples
obtained soon after recovery from induction chemother-
apy induced aplasia. As shown in Figure 2, 23 patients
out of 71, although in CR, displayed WT1 values above
the normal range with a median value of 112 WT1 copies
(mean 292±638, range 23-2840). By contrast, in 48 out of
71 patients who entered CR, the amount of WT1 tran-
script measured after induction treatment fell within the
range detected in healthy controls with a median value of
WT1 of 6 copies/104 ABL (mean=7.1±5, range 0.5-19).
Interestingly, all patients showing WT1 values above the
normal upper limit after induction chemotherapy
relapsed after a median of seven months (range 4-16). As
shown in Figure 3,  21 of the 48 patients with normal
WT1 values after chemotherapy relapsed after a median
of 12 months from diagnosis (range 6-44 months) and 27
patients persisted in CR after a median of 28 months of
follow-up (range 12-60 months) (Figure 1).  No significant
differences were observed between WT1 transcript levels
detected at CR after induction chemotherapy in the
cohort of 27 out of 48 patients who subsequently persist-
ed in remission when compared with the 21 who
relapsed during follow-up (p=0.33). In all patients who
reached  a normal WT1 value after induction chemother-
apy and later relapsed during follow-up, at least one
Figure 1. WT1 expression at diagnosis and during follow-up of 27
patients in CR characterized by WT1 values within the normal
range after induction chemotherapy. All these patients persisted in
CR during follow-up. WT1 never increased above the normal range
during follow-up. The broken line represents the upper normal
limit.
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abnormal value was detected before relapse. The detec-
tion of an abnormal WT1 value preceded by 1-6 months
(mean 2.4 months) the hematologic relapse. In none of
the 27 patients who persisted in CR were abnormal WT1
values detected during follow-up. Compared with the 21
patients who relapsed after achieving normal WT1 levels
after induction therapy, the patients who showed abnor-
mal WT1 levels after chemotherapy underwent disease
relapse after a significantly shorter time interval from
diagnosis to relapse (median of 7 vs. 12 months; mean
8.3±3.3  vs. 14.8±9.4; p=0.0033). In the 11 patients resist-
ant to chemotherapy, the WT1 transcript amount persist-
ed at very high levels after chemotherapy with a median
value of 5,647 (mean 13,886±27,548) WT1 copies/104
ABL copies at diagnosis and a median of 3,180 (mean
10,232±19,103) after induction chemotherapy.  This
study shows that longitudinal quantitative analysis of
WT1 expression in the PB of AML patients may provide
relevant prognostic information by early identification of
patients at highest risk of relapse. Doubts about the use
of WT1 expression as a marker for MRD monitoring in
leukemia have mainly been based on the existing back-
ground expression derived from normal hematopoietic
cells.20 The recent advent of RQ-PCR technique for more
precise and standardized quantification has allowed  this
problem to be partially overcome by identifying thresh-
old values distinguishing the WT1 transcript amounts
expressed in normal subjects from those of leukemic
cells.10-16 We found that such discrimination, which is
extremely relevant for the purpose of clinical studies of
MRD, is best accomplished by using PB instead of BM,
due to considerably lower WT1 expression levels and
smaller individual variability in normal PB compared
with BM. Whether WT1 amount at diagnosis in leukemia
patients has any prognostic significance is still a subject
of debate.21-23 In our study, the WT1 transcript level at
diagnosis seems not to be correlated with patient out-
come. The most important information derived from our
study comes from WT1 expression analysis after induc-
tion chemotherapy, when the standard criteria define the
patient as being in complete remission, and morphologi-
cal criteria and flow cytometry on PB did not reveal the
presence of circulationg blast cells. Since WT1 is overex-
pressed in the large majority of AML cases, it could rep-
resent the ideal marker for MRD evaluation. Recently,
Lapillonne et al.24 demonstrated that WT1 quantitative
assessment after a first course of induction treatment in
BM samples represents the ideal tool to identify pedi-
atric acute leukemia patients at high risk of relapse. Our
data demonstrate that the sensitivity of WT1 analysis in
PB is equal if not better than BM. Furthermore, it iden-
tifies a precise time point, in particular soon after the
first cycle of chemotherapy for the evaluation of  WT1
transcript with the intent of identifying patients at high
risk of relapse. At this time point, WT1 copy number
allows a better assessment of the quality of remission.
In particular, the observation that abnormal WT1 values
in PB after the first course of therapy in CR patients
strictly correlate with relapse represents an important
achievement as it would allow clinicians to intensify
post-induction therapy and use more aggressive consol-
idation cycle to prevent relapse. From our study, how-
ever, we have seen that approximately half of the
patients who reach normal WT1 values after induction
chemotherapy relapse, although the reappearance of
disease occurs later compared with those who do not
reach the normalization of WT1. Therefore, only the
abnormal WT1 values after induction treatment are
Figure 2. WT1 expression at diagnosis
and during follow-up of 23 patients in
CR characterized by WT1 values above
the normal upper limit in PB after
induction chemotherapy. All these
patients relapsed after a median of
seven months from diagnosis. R:
relapse. The broken line represents the
upper normal limit. 
Figure 3. WT1 expression at diagnosis
and during follow-up of 21 patients in
CR characterized by WT1 values within
the normal range after induction
chemotherapy. All these patients
relapsed after a median of 13 months
from diagnosis. The broken line repre-
sents the upper normal limit.
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unfailingly predictive of relapse. For the remaining
patients, a stringent molecular follow-up post-remission
is recommended since this may allow relapse to be pre-
dicted some months before its occurrence, when the
conventional methods used are still unable to identify
the reappearance of leukemic cells. The ongoing efforts
to standardize real time methods of WT1 assessment
and the introduction of rigorous, internationally accept-
ed controls will enable RQ-PCR to become a robust and
routine basis for diagnostic and prognostic procedures. 
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